Earnings Call · Q3 FY2021·2021-11-15

Q3 21EPS -21.31%·Rev n/aQ2 21EPS +18.92%·Rev n/aQ1 21EPS +5.41%·Rev n/aQ4 20EPS -4.00%·Rev n/a⚠ consensus missing

BiomX Inc. PHGE

Marina Wolfson — Senior Vice President of Finance

Jonathan Solomon — Chief Executive Officer

In consultation with cystic fibrosis therapeutic development network, BiomX plans to conduct a Phase Ib/IIa trial comprised of 2 parts

−4.8%1d on move date−4.9% vs SPY3d−14.1%5d−20.1%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more PHGE calls or request research access.

More PHGE calls Browse calls Request research access